Key Points
- Director Howard Welgus sold 10,000 shares at an average price of $25.05 for proceeds of $250,500, leaving him with 59,744 shares (a 14.34% reduction in his position).
- Multiple senior executives and a director disclosed insider sales totaling roughly 46.7k shares (about $1.2M in proceeds), a clustered selling pattern that could amplify near-term negative sentiment on the stock.
- Despite the insider sales, analysts maintain a consensus "Moderate Buy" with an average target near $29.20 (some firms like Mizuho have targets as high as $37), while the stock trades in the mid-$20s with a market cap around $3.19 billion.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) CFO Latha Vairavan sold 1,320 shares of the firm's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $33,660.00. Following the completion of the transaction, the chief financial officer owned 63,607 shares of the company's stock, valued at $1,621,978.50. The trade was a 2.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Arcutis Biotherapeutics Stock Performance
Shares of NASDAQ ARQT opened at $26.08 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The stock has a 50 day moving average price of $28.23 and a 200 day moving average price of $22.43. The stock has a market capitalization of $3.19 billion, a PE ratio of -72.44 and a beta of 1.70. Arcutis Biotherapeutics, Inc. has a 52 week low of $11.13 and a 52 week high of $31.77.
Analyst Ratings Changes
A number of research analysts have recently commented on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, January 23rd. Zacks Research downgraded Arcutis Biotherapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 29th. Mizuho increased their price target on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an "outperform" rating in a research note on Friday, November 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Arcutis Biotherapeutics in a report on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.20.
View Our Latest Stock Report on ARQT
More Arcutis Biotherapeutics News
Here are the key news stories impacting Arcutis Biotherapeutics this week:
- Positive Sentiment: Several analysts have maintained buy ratings and raised price targets (Needham, Mizuho, HC Wainwright among others); consensus remains a "Moderate Buy" with an average target near $29.20 — a positive catalyst that could limit downside from insider selling. MarketBeat ARQT analyst notes
- Neutral Sentiment: Short-interest data reported as effectively 0 shares as of Feb. 3 appears anomalous (NaN increase and 0.0 days-to-cover); this reading is unlikely to be meaningful for immediate price action. Institutional/hedge-fund position changes reported recently were small and incremental. MarketBeat short interest & institutional holdings
- Negative Sentiment: Multiple senior executives and a director disclosed sales totaling tens of thousands of shares (~46.7k shares across the filings, roughly $1.2M in proceeds across the named trades). Notable filings include Todd Watanabe (19,833 shares at ~$25.50), Masaru Matsuda (40,638 shares at ~$25.28), Director Howard Welgus (10,000 shares) and others (CFO Latha Vairavan, Patrick Burnett, Larry Todd Edwards). Coordinated/clustered insider selling can amplify near-term negative sentiment and pressure the stock. InsiderTrades alert on recent ARQT sales Todd Watanabe Form 4
Hedge Funds Weigh In On Arcutis Biotherapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Independent Advisor Alliance raised its stake in Arcutis Biotherapeutics by 25.1% in the 4th quarter. Independent Advisor Alliance now owns 25,303 shares of the company's stock worth $735,000 after purchasing an additional 5,069 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at approximately $414,000. Trek Financial LLC bought a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at approximately $540,000. Ballentine Partners LLC acquired a new stake in Arcutis Biotherapeutics during the fourth quarter worth approximately $307,000. Finally, RFG Advisory LLC acquired a new position in Arcutis Biotherapeutics in the 4th quarter valued at $1,577,000.
Arcutis Biotherapeutics Company Profile
(
Get Free Report)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
